MLYS vs. NRIX, OCS, LQDA, PROC, MRNS, ICPT, EWTX, LYEL, ORIC, and IGMS
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Nurix Therapeutics (NRIX), Oculis (OCS), Liquidia (LQDA), Procaps Group (PROC), Marinus Pharmaceuticals (MRNS), Intercept Pharmaceuticals (ICPT), Edgewise Therapeutics (EWTX), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry.
Mineralys Therapeutics (NASDAQ:MLYS) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking.
Nurix Therapeutics received 27 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 64.81% of users gave Nurix Therapeutics an outperform vote.
In the previous week, Mineralys Therapeutics and Mineralys Therapeutics both had 2 articles in the media. Mineralys Therapeutics' average media sentiment score of 1.61 beat Nurix Therapeutics' score of 1.24 indicating that Mineralys Therapeutics is being referred to more favorably in the media.
Mineralys Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics.
Mineralys Therapeutics currently has a consensus target price of $36.00, indicating a potential upside of 278.55%. Nurix Therapeutics has a consensus target price of $27.44, indicating a potential upside of 249.17%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Mineralys Therapeutics is more favorable than Nurix Therapeutics.
61.7% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 90.4% of Nurix Therapeutics shares are owned by institutional investors. 7.2% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Mineralys Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -258.37%. Mineralys Therapeutics' return on equity of -27.88% beat Nurix Therapeutics' return on equity.
Summary
Mineralys Therapeutics beats Nurix Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
